Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,064 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Use of Hypomethylating Agents for MDS May Activate Oncogene

New research has found that demethylation and up-regulation of an oncogene after treatment with a hypomethylating agent can occur and warrants further study.

Case Series Suggests Daratumumab Associated with Ocular Events

Ocular events included post-marketing cases of acute angle-closure glaucoma, myopic shift, and choroidal effusions.

S1PR Modulator Mocravimod Granted Fast Track Designation

The designation is in combination with allogeneic hematopoietic stem cell transplant for post-remission therapy in patients with acute myeloid leukemia.

Magrolimab Plus Azacitidine Demonstrates Durable Response in Patients with TP53-Mutated AML

Magrolimab is a first-in-class, anti-CD47 monoclonal antibody and macrophage checkpoint inhibitor that blocks CD47.

Teclistamab Plus Daratumumab Shows Improved Clinical Efficacy in Pretreated Multiple Myeloma

The BCMA and monoclonal antibody combination resulted in a 78% overall response rate.

Obinutuzumab Demonstrates Long-Term Benefit Over Rituximab in Patients with Previously Untreated Fol

The phase III GALLIUM study demonstrated improved PFS with obinutuzumab plus chemotherapy.

Global Hematopoietic Stem Cell Transplantation Rates Continue to Grow

The Worldwide Network of Blood and Marrow Transplantation recently released a study reporting on the global activity trends of transplantations between 2014 and 2016.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top